

## Special Issue

# Infectious Agents and Cancer in Children and Adolescents

### Message from the Guest Editors

The intricate interplay between infectious agents, the immune system, and tumor development is gaining attention. Prior infections may aid neoplastic cell clearance through immunological memory, but evidence suggests infectious agents' involvement in malignancies beyond oncogenic viruses. Infections influence immunological status, affecting Th1/Th2 polarization and immunosurveillance success. Chronic low-grade inflammation linked to infections raises tumorigenesis risk. Oncolytic viruses have revolutionized oncology by lysing neoplastic cells or modifying the tumor microenvironment. Infections also pose a major threat to cancer patients, particularly with intensified chemotherapy. Join us in this Special Issue to explore the role of infectious agents in cancer pathogenesis, treatment, and complications through original research articles and state-of-the-art reviews.

### Guest Editors

Dr. Emmanouel Hatzipantelis

2nd Department of Paediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece

Dr. Eleni Tsotridou

1st Department of Pediatrics, Aristotle University, Ippokratio General Hospital, Thessaloniki, Greece

### Deadline for manuscript submissions

15 May 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/202370](https://mdpi.com/si/202370)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)